CONCURRENT CHEMORADIATION

Nimotuzumab significantly increases survival in head, neck cancer: Tata Memorial study

​ Patients with head and neck cancer who received nimotuzumab in combination with concurrent radiotherapy and cisplatin had a 10-year overall survival rate of 33.5 per cent, compared to 22.5 per cent who received only radiotherapy and cisplatin. The median overall survival improved from 2.78 years in the standard treatment arm to 3.69 years in the nimotuzumab arm.